BrainsWay Reports Expansion of Adolescent Depression Coverage for Deep TMS Therapy

BrainsWay Ltd. announced that Optum Behavioral Health, a health services company with over 48 million covered lives, has expanded its medical policy to include coverage for Deep TMS™ therapy for adolescents aged 15 and older diagnosed with major depressive disorder (MDD). This expansion aligns with other major insurers covering the therapy for this age group, collectively covering approximately 180 million lives. The company highlights the significant public health challenge posed by adolescent depression, the limited treatment options, and the potential of Deep TMS as an effective, non-drug alternative. BrainsWay’s Deep TMS is FDA cleared as an adjunct therapy for adolescent depression, demonstrating clinically proven efficacy. The company, a leader in noninvasive neurostimulation, aims to increase global access to its treatments, which currently include FDA-cleared indications for MDD, obsessive-compulsive disorder, and smoking addiction.